HealthDay News — The annual incidence of treatment-related acute myeloid leukemia (tAML) has increased, in addition to an increase in the distribution of primary cancers, defined as the first ...

Sellas will present new data on its CDK9 inhibitor SLS009 at the American Association for Cancer Research (AACR) meeting on April 21. ・Preclinical findings showed SLS009 triggered leukemia cell death ...

AML related to cancer therapy has been recognized as a distinct clinical entity for more than 40 years. Genetic mutations, ...

HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next segment on its CEO Corner, a platform ...

'You feel incredibly helpless' ...

Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.

Among 9,841 patients with AML, 636 (6.5%) had tAML. The annual tAML incidence increased from 0.13 per 100,000 population in ...

The University of Colorado Anschutz Gates Institute has received Investigational New Drug clearance from the U.S. Food and Drug Administration, marking the first chimeric antigen receptor (CAR) T-cell ...

New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or ...

Faith Hinitt was diagnosed with a rare cancer called acute myeloid leukemia (AML) at the age of 25. The 27-year-old needed to ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML ...

WASHINGTON, Jan. 14, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment in a new sub-study of its Beat ...